Deletion 5q MDS: molecular and therapeutic implications

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• The most frequent cytogenetic abnormality in MDS is heterozygous, interstitial deletion of chromosome 5q, defining the 5q- syndrome.
• The 5q- syndrome is linked to specific clinical features and sensitivity to lenalidomide therapy.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the 5q- syndrome in myelodysplastic syndromes.
• To investigate the role of haploinsufficiency of genes on chromosome 5q in hematopoiesis.
• To understand the contribution of specific genes and microRNAs to the disease phenotype.

Main Methods:

• Analysis of cytogenetic abnormalities in MDS patients.
• Investigation of gene and microRNA function in hematopoiesis.
• Assessment of the impact of p53 pathway activation and modulation on erythropoiesis.

Main Results:

• Haploinsufficiency, not homozygous inactivation, of 5q genes drives the MDS phenotype in 5q- syndrome.
• RPS14 haploinsufficiency activates the p53 pathway, causing macrocytic anemia; p53 loss rescues erythropoiesis.
• Other genes and microRNAs (miR-145, miR-146a) contribute to abnormal megakaryopoiesis and clonal advantage.

Conclusions:

• The 5q- syndrome results from the integrated effects of haploinsufficiency for multiple key genes and microRNAs on chromosome 5q.
• Altered hematopoiesis, particularly erythropoiesis and megakaryopoiesis, is driven by these genetic imbalances.
• Understanding these mechanisms may inform targeted therapies for MDS with 5q deletion.